Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708834 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 772
- Enrollment target
NCT04708834: Clinical Trial Phase 3 study, sponsored by Biohaven Pharmaceuticals.
NCT04708834 is a Phase 3 study that was terminated before completion, run by Biohaven Pharmaceuticals. The registered enrollment target is 772 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04708834, a Phase 3 study, was terminated before completion, sponsored by Biohaven Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 772 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
Primary Outcome
Percent change in treatment emergent adverse events, and clinical significant abnormalities in ECG's and lab values after Baseline.
Interventions
- DRUG Troriluzole (BHV-4157)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 772 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-02-13 |
| Phase | Phase 3 |
Why NCT04708834 stopped before completion
NCT04708834 is an interventional study that assigns participants to a tested intervention. The registered 772 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Troriluzole (BHV-4157) is the first listed.
NCT04708834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04708834 about?
NCT04708834 is a clinical study titled "Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder". The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
What is the current status of trial NCT04708834?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 772 participants. The study started on 2021-03-30. Estimated completion is 2026-02-13.
What interventions are being tested in trial NCT04708834?
The interventions under investigation include: Troriluzole (BHV-4157) (DRUG).
Who is sponsoring clinical trial NCT04708834?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04708834's enrollment target sits among peer trials
772 440th of 2000 higher than 1,561 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05977348 · 770 participants · NA
Increasing Food Literacy in Preschoolers to Reduce Obesity Risk
- NCT06376994 · 770 participants · Phase 3
Multi-Center Clean Air Randomized Controlled Trial in COPD
- NCT06824467 · 770 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- NCT06907173 · 770 participants · Phase 3
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI